Madrigal Pharmaceuticals Inc logo

Madrigal Pharmaceuticals Inc

1
NAS:MDGL (USA)  
$ 311.40 +0.53 (+0.17%) 12:51 PM EST
At Loss
P/B:
8.72
Volume:
75.91K
Avg Vol (2M):
495.73K
Trade In:
Volume:
75.91K
At Loss
Avg Vol (2M):
495.73K

Business Description

Description
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
Name Current Vs Industry Vs History
Cash-To-Debt 8.38
Equity-to-Asset 0.72
Debt-to-Equity 0.15
Debt-to-EBITDA -0.24
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 10.98
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 58.79
9-Day RSI 51.97
14-Day RSI 52.31
6-1 Month Momentum % 24.79
12-1 Month Momentum % 47.81

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.98
Quick Ratio 5.93
Cash Ratio 5.62
Days Inventory 726.2
Days Sales Outstanding 88.77
Days Payable 3170.08

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.6
Shareholder Yield % -9.79

Financials (Next Earnings Date:2025-02-28 Est.)

MDGL's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:MDGL

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Madrigal Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 76.813
EPS (TTM) ($) -25.12
Beta -1.21
Volatility % 55.99
14-Day RSI 52.31
14-Day ATR ($) 13.637571
20-Day SMA ($) 315.0695
12-1 Month Momentum % 47.81
52-Week Range ($) 168.2462 - 368.29
Shares Outstanding (Mil) 21.81

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Madrigal Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Madrigal Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Madrigal Pharmaceuticals Inc Frequently Asked Questions

What is Madrigal Pharmaceuticals Inc(MDGL)'s stock price today?
The current price of MDGL is $311.40. The 52 week high of MDGL is $368.29 and 52 week low is $168.25.
When is next earnings date of Madrigal Pharmaceuticals Inc(MDGL)?
The next earnings date of Madrigal Pharmaceuticals Inc(MDGL) is 2025-02-28 Est..
Does Madrigal Pharmaceuticals Inc(MDGL) pay dividends? If so, how much?
Madrigal Pharmaceuticals Inc(MDGL) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1